Jardine, Meg J <br/><br/>
Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial.  [electronic resource] 

 -  Journal of the American Society of Nephrology : JASN  05 2020 
 - 1128-1139 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1533-3450 
<br/><br/><label>Standard No.: </label>10.1681/ASN.2019111168  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Albuminuria--drug therapy<br/>Canagliflozin--adverse effects<br/>Cardiovascular Diseases--epidemiology<br/>Diabetes Mellitus, Type 2--complications<br/>Diabetic Nephropathies--drug therapy<br/>Double-Blind Method<br/>Female<br/>Humans<br/>Kidney--physiopathology<br/>Kidney Tubules, Proximal--drug effects<br/>Male<br/>Middle Aged<br/>Risk<br/>Sodium-Glucose Transporter 2 Inhibitors--adverse effects<br/>Treatment Outcome